Abel Hall LLC’s Lexeo Therapeutics LXEO Stock Holding History

Abel Hall LLC’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$42.7K	Buy	+12,642	New	+$57.2K	0.01%	841

Other funds holding LXEO

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Abel Hall LLC's LXEO Position: Q3 2026 in Review

Abel Hall LLC opened a new position in Lexeo Therapeutics (LXEO) in Q3 2026: 12,642 shares worth $42.7K. The stake represents 0.01% of the portfolio and ranks #841 among its holdings.

13 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.

Abel Hall LLC held 12,642 shares of Lexeo Therapeutics worth $42.7K as of Q3 2026.
Lexeo Therapeutics was a new Abel Hall LLC position in Q3 2026.
Lexeo Therapeutics made up 0.01% of Abel Hall LLC's portfolio in Q3 2026, its #841 holding.
13 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.